Hot Stocks: Brokerages on Orchid Pharma, D-Mart, NOCIL and Chola Investment

December 8, 2023

Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).

More To Explore

Nifty eyes consolidation, key support at 23,800: Sudeep Shah of SBI Securities

“Nifty IT is witnessing an outperformance, and this could witness further strength in the coming few sessions. After marking a high of 43,645 on September

November 9, 2024

8 smallcap stocks that gained for five days in a row

In the five trading sessions leading up to November 8, the Sensex index posted a slight decline, closing lower in three days. Despite this modest

November 9, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003